No Data
No Data
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)
Gene Therapy Developers Rise on Comments From FDA's Makary
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 29% Dive
REGENXBIO Is Maintained at Neutral by Goldman Sachs